

Review

Oxidative Stress and Reactive Oxygen Species in Tumor Initiation and Progression

Ruchismita Manna

Lecturer, Amity University Kolkata, Major Arterial Road, AA II, Newtown, Kadampukur, West Bengal 700135

Corresponding Author:

Dr. Ruchismita Manna

Email:

mannaruchismita@gmail.com

Conflict of interest: NIL

Article History

Received: 03/09/2025

Accepted: 22/09/2025

Published: 28/10/2025

Abstract:

Oxidative stress and reactive oxygen species (ROS) have gained significant attention as key players in the initiation and progression of various cancers. The imbalance between ROS production and the body's antioxidant defenses creates a cellular environment conducive to genetic mutations, inflammation, and alterations in cellular signaling pathways. This paper explores the role of oxidative stress and ROS in tumorigenesis, examining how they contribute to DNA damage, genomic instability, and the activation of oncogenes. Moreover, we discuss the complex relationship between ROS and tumor progression, emphasizing their influence on angiogenesis, metastasis, and resistance to therapy. Furthermore, the potential of antioxidant strategies and ROS-targeting therapies for cancer prevention and treatment are explored. This review highlights the necessity of understanding the molecular mechanisms through which oxidative stress and ROS influence cancer development, with the goal of identifying novel therapeutic targets and improving clinical outcomes.

Keywords: Oxidative stress, Reactive oxygen species, Tumor initiation, Tumor progression, Cancer, DNA damage, Genomic instability, Oncogenes, Angiogenesis, Metastasis, Antioxidants, Cancer therapy, Tumor microenvironment

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

1.1 Introduction:

Cancer remains one of the leading causes of morbidity and mortality worldwide, with its complex etiology involving genetic, environmental, and lifestyle factors. Among these, oxidative stress and reactive oxygen species (ROS) have emerged as pivotal contributors to tumor initiation and progression. ROS, which include free radicals such as superoxide anion (O_2^-), hydroxyl radical (OH^\bullet), and non-radical species like hydrogen peroxide (H_2O_2), are generated as byproducts of normal cellular metabolism, particularly within the mitochondria. Under normal conditions, cells maintain a balance between ROS production and antioxidant defenses. However, when ROS levels exceed the capacity of the antioxidant system, oxidative stress ensues, leading to cellular damage.(1)

In the context of cancer, oxidative stress plays a dual role. On one hand, elevated ROS levels can induce DNA damage, mutation, and genomic instability, which are hallmarks of cancer initiation. On the other hand, ROS can influence various cellular signaling pathways that regulate cell proliferation, apoptosis, and survival, thereby fostering the growth and metastasis of established tumors. Furthermore, oxidative stress contributes to the tumor microenvironment by enhancing angiogenesis, promoting immune evasion, and enabling cancer cells to resist therapeutic interventions.(2)

This introduction sets the stage for understanding the intricate relationship between ROS and cancer biology, underscoring their contribution not only to the early stages of carcinogenesis but also to the evolution of aggressive tumor phenotypes. As such, ROS have become critical targets for developing novel cancer prevention and treatment strategies,

highlighting the importance of further exploring the molecular mechanisms linking oxidative stress to cancer.

1.2 Overview of Cancer and Its Complex Etiology

Cancer is a group of diseases characterized by uncontrolled cell growth and spread to other parts of the body. It results from a complex interplay of genetic mutations, environmental factors, and lifestyle choices.(3) The etiology of cancer involves various mechanisms, including the accumulation of genetic alterations, disruption of normal cellular processes, and changes in the tumor microenvironment. Factors such as carcinogen exposure, inherited genetic predisposition, inflammation, and immune evasion contribute to the development and progression of cancer, making its origins multifaceted.(4)

1.3 The Role of Oxidative Stress in Cellular Homeostasis

Cellular homeostasis refers to the stable, balanced condition of the cell, where vital processes such as metabolism, growth, and repair function properly. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the cell's ability to neutralize them with antioxidants. (5) This imbalance can disrupt normal cellular processes and lead to damage in lipids, proteins, and DNA, affecting the cell's function and survival. In healthy cells, oxidative stress is tightly regulated, but when this regulation is disrupted, it can contribute to diseases, including cancer.(6)

1.4 Understanding Reactive Oxygen Species (ROS)

Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen, such as superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), and hydroxyl radical ($OH\bullet$). These molecules are natural byproducts of cellular metabolism, particularly from the mitochondrial respiratory chain.(7) Although ROS play essential roles in normal cellular processes like immune defense and signaling, their overproduction can lead to oxidative damage. Excessive ROS are implicated in several diseases, including cancer, where they can cause mutations, genomic instability, and promote tumorigenesis.(8)

1.5 Mechanisms of ROS Production in Normal and Cancer Cells

ROS are primarily produced in the mitochondria during oxidative phosphorylation as part of cellular respiration. However, cells can also generate ROS

through enzymes such as NADPH oxidases, xanthine oxidase, and cytochrome P450.(9) In normal cells, ROS are produced at controlled levels and are regulated by antioxidant enzymes like superoxide dismutase (SOD), catalase, and glutathione peroxidase. In cancer cells, however, ROS production is often dysregulated. Due to factors such as increased mitochondrial activity, altered metabolic pathways (e.g., the Warburg effect), and the tumor microenvironment (hypoxia, inflammation), cancer cells tend to produce elevated levels of ROS, which can drive tumor initiation and progression.(10)

1.6 The Balance Between ROS and Antioxidant Defenses

Under normal conditions, cells maintain a delicate balance between ROS generation and antioxidant defenses. Antioxidants, which include both enzymatic and non-enzymatic systems, neutralize ROS and prevent cellular damage.(11) Enzymatic antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase catalyze the breakdown of ROS into less harmful molecules, while non-enzymatic antioxidants, such as vitamins C and E, scavenge ROS directly. When this balance is disrupted, either by excessive ROS production or insufficient antioxidant activity, oxidative stress occurs, leading to cellular damage, inflammation, and the potential development of diseases like cancer. In cancer cells, this balance is often tipped in favor of ROS production, which supports tumor growth, invasion, and resistance to therapies.(12)

1.7 Defining Oxidative Stress and Its Implications for Cellular Function

Oxidative stress refers to the condition in which the production of reactive oxygen species (ROS) overwhelms the cell's antioxidant defenses, leading to cellular damage. ROS are highly reactive molecules that can damage lipids, proteins, and nucleic acids, compromising cellular integrity. (13) When oxidative stress is chronic or unregulated, it disrupts critical cellular functions such as signal transduction, gene expression, and cellular repair mechanisms. This imbalance plays a significant role in aging, degenerative diseases, and cancer. In cancer, oxidative stress can drive mutations, inflammation, and immune evasion, all of which contribute to the initiation and progression of tumors.(14)

1.8 The Dual Role of ROS in Cancer Development

Reactive oxygen species (ROS) have a dual role in cancer development. On one hand, excessive ROS production can lead to cellular damage, mutations, and genomic instability, which initiate the process of carcinogenesis.(15) On the other hand, ROS also act as signaling molecules that regulate various cellular pathways involved in tumor progression. Elevated ROS levels can activate pathways that promote tumor cell proliferation, survival, invasion, and metastasis. This complex interplay between ROS as both damaging agents and signaling mediators underscores their crucial role in the initiation and progression of cancer.(16)

1.9 DNA Damage and Genomic Instability Induced by ROS

ROS-induced DNA damage is a primary mechanism by which oxidative stress contributes to cancer initiation. ROS can cause a variety of DNA lesions, including base modifications, single-strand breaks, double-strand breaks, and crosslinking of DNA strands.(17) If these lesions are not efficiently repaired, they can lead to mutations and chromosomal instability, which are hallmarks of cancer cells. Genomic instability allows for the accumulation of mutations in critical genes, including tumor suppressor genes and oncogenes, driving tumorigenesis. The persistence of DNA damage in a cell due to oxidative stress contributes to the development of malignant phenotypes.(18)

1.10 Mutations and Oncogene Activation in Response to Oxidative Stress

Oxidative stress can cause mutations in the DNA of normal cells, leading to the activation of oncogenes, which are genes that promote uncontrolled cell growth and survival. These mutations are typically induced by ROS interacting with DNA, causing base pair modifications, deletions, or translocations.(19) Oncogenes such as Ras, Myc, and EGFR are frequently mutated or overexpressed in various cancers. These mutations enhance cell proliferation, inhibit apoptosis, and promote cell survival, contributing to the transformation of normal cells into cancer cells. Furthermore, ROS can also contribute to the inactivation of tumor suppressor genes, amplifying the oncogenic effect.(20)

1.11 ROS-Mediated Signaling Pathways in Tumor Progression

ROS are key regulators of various signaling pathways that drive tumor progression. Elevated ROS levels can activate multiple signaling cascades, such as the mitogen-activated protein kinase

(MAPK), phosphoinositide 3-kinase (PI3K)/Akt, and nuclear factor kappa B (NF- κ B) pathways, all of which promote cancer cell proliferation, survival, and metastasis. ROS can also modulate cell cycle progression, angiogenesis (the formation of new blood vessels), and the epithelial-to-mesenchymal transition (EMT), a process critical for metastasis.(22) Additionally, ROS influence immune system interactions, allowing cancer cells to evade immune surveillance. By modifying these key pathways, ROS play a significant role in driving tumor growth and metastasis.(21)

1.12 The Role of ROS in Tumor Growth and Survival

In tumors, ROS are not only involved in their initiation but also in their continued growth and survival. Cancer cells often exhibit increased ROS levels due to metabolic changes such as enhanced glycolysis (the Warburg effect) or mitochondrial dysfunction.(23) These elevated ROS levels create an environment that supports the survival of cancer cells by activating pro-survival signaling pathways, such as the PI3K/Akt pathway. ROS also contribute to the ability of tumors to resist therapeutic interventions by promoting cellular adaptation and reducing the effectiveness of chemotherapy and radiation. Additionally, cancer cells utilize ROS to maintain their aggressive behavior, including continuous proliferation and invasion into surrounding tissues. Thus, ROS are integral to maintaining the malignant characteristics of tumors.(24)

1.13 Oxidative Stress and the Tumor Microenvironment

The tumor microenvironment (TME) is the complex and dynamic environment surrounding a tumor, including cells, extracellular matrix, and various signaling molecules. Oxidative stress plays a critical role in shaping the TME by influencing cellular behavior and intercellular interactions.(25) Increased ROS production within the TME can create a state of chronic inflammation, promote the secretion of pro-inflammatory cytokines, and alter extracellular matrix composition. These changes can enhance tumor cell survival, proliferation, and invasion, as well as contribute to the recruitment of immune cells and fibroblasts that further support tumor growth. ROS also induce hypoxia, which leads to the activation of hypoxia-inducible factors (HIFs), further enhancing the aggressiveness of the tumor. The interplay between oxidative stress and

the TME is essential for cancer progression, promoting a more favorable environment for tumor cells to thrive and metastasize.(26)

1.14 ROS Influence on Angiogenesis and Tumor Vasculature

Angiogenesis, the process by which new blood vessels form from existing ones, is essential for tumor growth and metastasis as it provides oxygen and nutrients to growing tumors. ROS are key regulators of angiogenesis in the tumor microenvironment.(27) High levels of ROS can activate several signaling pathways, including those involving vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs), both of which promote blood vessel formation. ROS also induce the stabilization of hypoxia-inducible factors (HIFs) under low oxygen conditions, which in turn upregulate the expression of pro-angiogenic factors. The ROS-mediated activation of these pathways not only supports the formation of new blood vessels but also contributes to the abnormal and dysfunctional vasculature often seen in tumors. This dysfunctional tumor vasculature facilitates further tumor progression by enhancing tumor cell invasion, metastasis, and resistance to therapy.(28)

1.15 Immune Evasion and Metastasis Promoted by Oxidative Stress

Oxidative stress contributes to the immune evasion of tumors by modulating the immune microenvironment. Elevated ROS levels can inhibit the function of immune cells, such as T lymphocytes and natural killer (NK) cells, which are essential for detecting and destroying tumor cells. ROS can also promote the recruitment of immunosuppressive cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which further dampen immune responses against the tumor.(29) Additionally, ROS can induce the expression of immune checkpoint molecules (e.g., PD-L1), which help tumors evade immune surveillance. Furthermore, oxidative stress enhances the epithelial-to-mesenchymal transition (EMT), a process by which cancer cells acquire migratory and invasive properties, facilitating metastasis. By influencing both the immune system and cellular behavior, ROS play a pivotal role in promoting cancer metastasis, allowing tumor cells to spread to distant sites and form secondary tumors.(30)

Section	Description
Introduction	Introduction to the role of oxidative stress and ROS in cancer biology.
Oxidative Stress and Reactive Oxygen Species (ROS)	Overview of ROS, their production, and their impact on cellular functions.
ROS and Tumorigenesis	How ROS contribute to the initiation and promotion of cancer through mutations and genetic instability.
DNA Damage and Genomic Instability	ROS-induced DNA damage and its consequences on genomic stability and tumorigenesis.
The Tumor Microenvironment and ROS	The role of oxidative stress in shaping the tumor microenvironment and supporting tumor growth.
ROS and Tumor Progression	The involvement of ROS in tumor progression, cell survival, and metastasis.
Angiogenesis and ROS	The impact of ROS on angiogenesis and the formation of abnormal tumor vasculature.
Immune Evasion and ROS	How ROS contribute to immune evasion and metastasis in cancer.
Therapeutic Implications of Targeting ROS	Exploring therapeutic strategies that target ROS to inhibit cancer progression.
Conclusion	Concluding remarks on the complex role of ROS in cancer initiation and progression and the future of therapeutic interventions.

Conclusion:

Oxidative stress and reactive oxygen species (ROS) play a central role in the initiation, progression, and metastasis of cancer. By disrupting the delicate balance between ROS production and antioxidant defenses, oxidative stress leads to cellular damage, genetic mutations, and genomic instability, all of

which are key contributors to cancer development. In addition to their direct DNA-damaging effects, ROS act as signaling molecules that regulate various cellular pathways involved in tumor growth, survival, angiogenesis, and immune evasion. The tumor microenvironment (TME), characterized by increased oxidative stress, further supports tumor

progression by fostering chronic inflammation, promoting angiogenesis, and creating conditions conducive to immune suppression and metastasis. ROS also drive the recruitment of cells and signaling pathways that sustain tumor growth and enable cancer cells to resist therapeutic interventions.

Given the complex and multifaceted role of ROS in cancer, targeting oxidative stress presents an attractive therapeutic strategy. By modulating ROS levels, either through antioxidant therapies or by enhancing ROS production selectively in tumor cells, it may be possible to interfere with tumor growth, enhance the effectiveness of existing treatments, and reduce metastasis. However, due to the dual nature of ROS in both tumor initiation and progression, careful consideration is required in designing therapies that balance ROS-induced damage and therapeutic benefits.

In summary, understanding the intricate relationship between oxidative stress, ROS, and cancer biology is crucial for identifying novel therapeutic strategies and improving clinical outcomes. Further research into the molecular mechanisms driving oxidative stress in cancer will pave the way for innovative approaches to prevent and treat cancer more effectively.

REFERENCES:

1. Mandal S, Mandal S. Topical Delivery of Sulfasalazine via Nanosponges-Loaded Hydrogels: A Novel Approach for Enhanced Psoriasis Management. *International Journal of Multidisciplinary Science and Innovation*. 2025 Apr 25:19-23.
2. Topi D, Dubey CK, Sharma S, Fasiha B, Mandal S. A Review of Plant-Based Natural Products for the Management of Diabetes: From Ethnobotany to Clinical Evidence. *International Journal of Natural Products and Alternative Medicine*. 2025 Mar 20:16-22.
3. Mandal S, Kumar M, Bhumika K, Ali S, Jahan I, Mandal S. Impact of Electronic Health Records and Automation on Pharmaceutical Management Efficiency: A Narrative Review. *International Journal of Health Sciences and Engineering*. 2025 Feb 17:21-36.
4. Kumar M, Manda S, Bhumika K, Ali S, Jahan I, Mandal S. Targeted Drug Delivery Systems in Oncology: A Review of Recent Patents and future directions. *International Journal of Health Sciences and Engineering*. 2025 Feb 17:37-57.
5. Mandal S. Advances and Future Prospects of Lipid-Based Nanocarriers in Targeted Cancer Therapy: A Comprehensive Review. *Current Cancer Drug Targets*. 2025 May 13.
6. Chatterjee S, Ahamed IN, Aggarwal M, Mandal S, Mandal S. Bioadhesive Self-Nanoemulsifying Drug Delivery Systems (BSNEDDS): A Novel Strategy to Enhance Mucosal Drug Absorption and Bioavailability. *International Journal of Multidisciplinary Science and Innovation*. 2025 Apr 25:24-7.
7. Velraj M, Bhyan B, Mishram R, Padhy RP, Mandal S. Recent Advances in the Isolation and Characterization of Antimicrobial Compounds. *International Journal of Natural Products and Alternative Medicine*. 2025 Mar 20:23-9.
8. Kotnala M, Porwal P, Mandal S, Mandal S. The Role of Plant Metabolites in Enhancing Immunomodulatory Responses in Autoimmune Diseases. *International Journal of Natural Products and Alternative Medicine*. 2025 Mar 20:30-6.
9. Monisha R, Jaqueline RS, Yadav K, Mandal S, Mandal S. Psychological Well-Being and Oral Health: The Role of Dentistry in Comprehensive Healthcare. *International Journal of Integrative Dental and Medical Sciences*. 2025 Mar 17:22-9.
10. Ismail A, KR PK, Mandal S. The Role of Oral Microbiota in Systemic Diseases: Bridging the gap between Dentistry and Medicine. *International Journal of Integrative Dental and Medical Sciences*. 2025 Mar 17:30-6.
11. Chatterjee S, Ahamed IN, Aggarwal M, Mandal S, Mandal S. Advances in Dental Biomaterials: Bridging Dentistry and Medicine for Improved Patient Outcomes. *International Journal of Integrative Dental and Medical Sciences*. 2025 Mar 17:1-6.
12. Kumar S, Mandal S, Bhyan B, Pandey A, Mishra R, Jain A. Digital Marketing Trends and Consumer Engagement: A Review. *The International Journal of Humanities, Social Sciences and Business Management*. 2025 Feb 27:6-10.
13. Mandal S, Mandal S. Cryptocurrency and the Future of Financial Markets: A Mini Review. *The International Journal of*

- Humanities, Social Sciences and Business Management. 2025 Feb 27:21-7.
14. Mandal S, Mandal S. Mesalamine Microemulsions for Crohn's Disease: A Review. *International Journal of Health Sciences and Engineering*. 2025 Feb 17:1-8.
 15. Bhumika K, Ali S, Jahan I, Kumar M, Mandal S, Mandal S. Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn's Disease Using Microemulsion Formulations. *International Journal of Health Sciences and Engineering*. 2025 Feb 17:16-20.
 16. Mandal S, Mandal S. Design and Evaluation of Liposomal Carriers for Targeted Delivery of siRNA In Cancer Therapy. *Current Pharmaceutical Letters And Reviews*. 2024 Oct 3:53-63.
 17. Bhumika K, Mandal S. Exploring the Chemical Composition and Cardioprotective Properties of *Plumeria obtusa* Using Advanced LC-MS/MS and Computational Methods in a Rabbit Model of Adriamycin Induced Myocardial Injury. *Current Pharmaceutical Letters And Reviews*. 2024 Oct 3:64-70.
 18. Mandal S, Mandal S. Green Biomaterials from plants: Harnessing Nature for Sustainable Solutions. *Current Pharmaceutical Letters And Reviews*. 2024 Oct 3:11-24.
 19. Shiva K, Mandal S. Development and Characterization of Bioinspired Cationic Lipid Nanocarriers for Enhanced Anti-Cancer Vaccine Delivery and Tumor Inhibition: In Vitro and In Vivo Evaluation. *Current Pharmaceutical Letters And Reviews*. 2024 Oct 3:71-7.
 20. Mandal S, Mandal S. Strategic Design and Synthesis of Betulinic Acid Derivatives for Targeted Cancer Treatment. *Current Pharmaceutical Letters And Reviews*. 2024 Oct 3:88-94.
 21. Jahan I, Mandal S. Development of Multi-Functional Nanocarriers for Combined Chemo and Photothermal Cancer Therapy. *Current Pharmaceutical Letters And Reviews*. 2024 Oct 3:78-87.
 22. Mandal S, Singh AP. Development and In-Vitro Characterization of Gentamycin Sulphate Nanoemulgel for Ophthalmic Applications. *International Journal of Drug Delivery Technology*. 2024;14(4):2347-58. doi: 10.25258/ijddt.14.4.56
 23. Suraj Mandal, Murraya koenigii: A Source of Bioactive Compounds for Inflammation and Pain Management, *Current Bioactive Compounds*; Volume 21, Issue , Year 2025, e15734072348822. DOI: 10.2174/011573407234882250324073439
 24. Jiyaul Hak, Iram Jahan, Nasiruddin Ahmad Farooqui, Atul Pratap Singh, Himanchal Sharma, Smriti Gohri, Anshu Gujjar, Suraj Mandal, Nanochips in the Field of Oncology: Advancements and Potential for Enhanced Cancer Therapy, *Current Cancer Therapy Reviews*; Volume 21, Issue , Year 2025, e15733947343855. DOI: 10.2174/0115733947343855241230115820
 25. Iram Jahan, Jiyaul Hak, Suraj Mandal, Shadab Ali, Sayad Ahad Ali, Nasiruddin Ahmad Farooqui, Isoquinoline Quaternary Alkaloid (IQA) Nano-dressings: A Comprehensive Review on Design Strategies, Therapeutic Applications, and Advancements in Transdermal Delivery for Chronic Wound Management, *Recent Advances in Drug Delivery and Formulation*; Volume 19, Issue , Year 2025, e26673878330005. DOI: 10.2174/0126673878330005250326060103
 26. Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. *Indian J of Pharmaceutical Education and Research*. 2023;57(3s):s481-s498.
 27. Mritunjay Kumar Ojha, Nalluri Satish Kumar, Umesh Kumar Sharma, Prakash Gadipelli, Suraj Mandal, Farah Deeba, Monalisa Khuntia, Hariballav Mahapatra (2024) Exploring the Potential of Artificial Intelligence in Optimizing Clinical Trial Design for More Efficient Drug Development. *Library Progress International*, 44(3), 9498-9510.
 28. Mandal S, Jaiswal DV, Shiva K. A review on marketed *Carica papaya* leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. *International Journal of Pharmaceutical Research*. 2020 Jul;12(3).
 29. Mandal S, Bhumika K, Kumar M, Hak J, Vishvakarma P, Sharma UK. A Novel Approach on Micro Sponges Drug

Delivery System: Method of Preparations, Application, and its Future Prospective. Indian J of Pharmaceutical Education and Research. 2024;58(1):45-63.

30. Mandal S, Vishvakarma P, Bhumika K. Developments in Emerging Topical Drug

Delivery Systems for Ocular Disorders. Curr Drug Res Rev. 2023 Dec 29. doi: 10.2174/0125899775266634231213044704. Epub ahead of print. PMID: 38158868.
